Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13001086 | 1.00 | DPP4 (0.39) | DPP4DPP8DPP9MAPTGAA | |
| SCHEMBL13070581 | 0.82 | BCHE (0.36) | DPP4DPP8DPP9MAPTHSD17B10 | |
| SCHEMBL13000959 | 0.81 | DPP4 (0.41) | DPP4DPP8DPP9MAPTGAA | |
| SCHEMBL13000985 | 0.81 | DPP4 (0.41) | DPP4DPP8DPP9MAPTGAA | |
| SCHEMBL3398657 | 0.81 | DPP4 (0.41) | DPP4DPP8DPP9MAPTGAA | |
| SCHEMBL3396500 | 0.79 | DPP4 (0.40) | DPP4DPP8DPP9MAPTGAA | |
| SCHEMBL13001053 | 0.79 | DPP4 (0.40) | DPP4DPP8DPP9MAPTGAA | |
| SCHEMBL3393338 | 0.79 | DPP4 (0.39) | DPP4DPP8DPP9MAPTGAA | |
| SCHEMBL13001094 | 0.79 | DPP4 (0.39) | DPP4DPP8DPP9MAPTGAA | |
| SCHEMBL14550873 | 0.78 | DPP4 (0.44) | DPP4DPP8DPP9MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2246347-B1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2016-09-28 | — | — | EP | disclosed |
| US-8415349-B2 | Dicycloazaalkane derivatives, preparation processes and medical uses thereof | Jiangsu Hansoh Pharmaceuticals Co., Ltd. (CN) | 2013-04-09 | — | — | US | disclosed |
| US-20130012705-A1 | DICYCLOAZAALKANE DERIVATIVES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2013-01-10 | — | — | US | disclosed |
| US-8304411-B2 | Dicycloazaalkane derivates, preparation processes and medical uses thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2012-11-06 | — | — | US | disclosed |
| US-20100311747-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2010-12-09 | — | — | US | disclosed |
| EP-2246347-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2010-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012705-A1 | DICYCLOAZAALKANE DERIVATIVES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | DPP4, DPP8, DPP7 | DPP4 1/4885DPP8 2/4885DPP9 5/4885 |
| US-20100311747-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | DPP4, DPP8, DPP7 | DPP4 1/4885DPP8 2/4885DPP9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.